The pitch — name stripped
A proprietary device that runs 200+ diagnostic blood tests from a single finger-prick drop, replacing the standard venous draw, deployed in retail pharmacies on a low per-test price.
Kasspian’s cold read on Theranos
Fatal flawThat the core technology — accurate results from a single drop of blood across hundreds of tests — actually works, and can be independently proven before a single real patient relies on it.
Theranos, founded by Elizabeth Holmes in 2003, raised around $700 million and reached a $9 billion valuation on a single promise: its 'Edison' device could run hundreds of diagnostic tests from one finger-prick drop of blood, cheaper and faster than the labs everyone else used. The board was packed with statesmen, the deals included Walgreens, and Holmes became the face of a healthcare revolution.
The device never worked as claimed. Many of the tests Theranos marketed were quietly run on modified commercial machines bought from rival companies; the proprietary Edison produced results that were often inaccurate. The one thing the entire $9 billion company depended on — the technology being real — had never been independently validated.
Wall Street Journal reporter John Carreyrou began exposing the gap between the claims and the reality in 2015, working from internal accounts and whistleblowers. Because these were medical tests, the stakes were not financial alone: real patients received results from a system that could not deliver them reliably.
Regulators moved in. Theranos voided or corrected years of test results, lost its lab certification, and unwound its Walgreens partnership. The valuation evaporated.
The company dissolved in 2018. Holmes was later convicted of fraud. The lesson the wreckage left behind is not subtle: a breakthrough nobody is allowed to verify is not a breakthrough.
Kasspian scored the stripped pitch 2/10 because the entire business rested on one unproven claim — the technology works — and the pitch offered no way to verify it. When a company's whole value depends on a single technical miracle, that miracle is the riskiest assumption, and it has to be provable to an outsider before anything else matters.
The deeper trap was that the hype made the question harder to ask. Star-studded boards, big partnerships, and a charismatic founder created social proof that stood in for the missing technical proof. Validation is not a famous name vouching for you; it's evidence a skeptic could check.
If your idea hinges on a hard technical breakthrough, prove the breakthrough first, in public, against an independent standard — before you sell it, before you scale it, before anyone relies on it. The order matters most when the cost of being wrong is measured in something other than money.
Theranos looked like a good idea too. Get the same honest read on yours — score, fatal flaw, market — in about 90 seconds.
One week, a dead startup and why it died. The next, a play to get your next customers.
No fluff, no spam. Unsubscribe anytime.